Boston Scientific Corporation $BSX Shares Sold by Strive Financial Group LLC

Strive Financial Group LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 77.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,419 shares of the medical equipment provider’s stock after selling 11,800 shares during the quarter. Strive Financial Group LLC’s holdings in Boston Scientific were worth $146,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC boosted its stake in Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $391,000 after acquiring an additional 132 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 139 shares during the period. Northwestern Mutual Investment Management Company LLC increased its position in Boston Scientific by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock worth $4,516,000 after buying an additional 140 shares during the last quarter. Kingsview Wealth Management LLC increased its stake in shares of Boston Scientific by 2.4% in the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after purchasing an additional 142 shares during the period. Finally, RiverFront Investment Group LLC raised its position in shares of Boston Scientific by 0.7% during the fourth quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider’s stock valued at $2,032,000 after buying an additional 150 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Insiders Place Their Bets

In related news, CEO Michael Mahoney bought 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Royal Bank Of Canada cut their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Jefferies Financial Group decreased their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Finally, Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

BSX stock opened at $47.85 on Friday. The stock has a market capitalization of $69.35 billion, a PE ratio of 19.37, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. The company’s 50-day moving average is $46.90 and its 200-day moving average is $55.74. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the company earned $0.75 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.